` TBPH (Theravance Biopharma Inc) vs S&P 500 Comparison - Alpha Spread

TBPH
vs
S&P 500

Over the past 12 months, TBPH has significantly outperformed S&P 500, delivering a return of +79% compared to the S&P 500's +14% growth.

Stocks Performance
TBPH vs S&P 500

Loading
TBPH
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TBPH vs S&P 500

Performance Gap Between TBPH and GSPC
HIDDEN
Show

Performance By Year
TBPH vs S&P 500

Loading
TBPH
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Theravance Biopharma Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Theravance Biopharma Inc
Glance View

Market Cap
895.9m USD
Industry
Pharmaceuticals

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

TBPH Intrinsic Value
HIDDEN
Show
Back to Top